Concord Drugs (Small Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Concord Drugs Limited |
|||
|
Price: ₹37.10 | ||
| 52 Week Low: ₹30.59 52 Week High: ₹61.50 |
|||
| Market Capital: 31.34 Crore (Smallcap) | |||
| -> | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Concord Drugs Share Price Target For 2024
- 1.1.1: Concord Drugs Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Concord Drugs Share Price Target For 2025
- 1.2.1: Concord Drugs Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Concord Drugs Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Concord Drugs Financial Performance
- 3.0.1: Is Concord Drugs A Good Buy For Long Term?
To predict the Concord Drugs's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Concord Drugs Share Price Target For 2024
The line chart displays the monthly closing prices of Concord Drugs with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Concord Drugs shares in 2024, see the table below.
Concord Drugs Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 39.05 (+5.25%) | Price Action: 29 Aug 2023 High |
| 2024 Target 2 | 38.65 (+4.17%) | Price Action: 10 Oct 2024 High |
| 2024 Target 1 | 38.25 (+3.09%) | Price Action: Dec 2022 High |
| Current Price | 37.10 | Concord Drugs's share price as of 26 Dec 2024 |
| Stop Loss 1 | 36.56 (-1.46%) | Price Action: 22 Aug 2024 High |
| Stop Loss 2 | 36.16 (-2.54%) | Price Action: 18 Apr 2024 Low |
| Stop Loss 3 | 35.79 (-3.54%) | Price Action: 28 Aug 2023 High |
Short-Term Technical Outlook
Current Technical Position: Concord Drugs is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 50-day moving average at ₹36.77 serves as the nearest technical reference point.
Historical Returns: 3-month: -0.38% | 6-month: -4.59% | 1-year: -37.88%
Concord Drugs Share Price Target For 2025
The line chart displays the monthly closing prices of Concord Drugs with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Concord Drugs shares in 2025, see the table below.
Concord Drugs Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 59.0 (+59.02%) | Price Action: 01 Jan 2024 High |
| 2025 Target 2 | 57.88 (+56.01%) | Price Action: 02 Jan 2024 High |
| 2025 Target 1 | 57.16 (+54.07%) | Fibonacci Extension Level 64.90% |
| Current Price | 37.10 | Concord Drugs's share price as of 26 Dec 2024 |
| Stop Loss 1 | 32.51 (-12.38%) | Price Action: 28 Sep 2023 Low |
| Stop Loss 2 | 32.1 (-13.48%) | Price Action: 21 Sep 2023 Low |
| Stop Loss 3 | 31.75 (-14.43%) | Price Action: May 2023 High |
Long-Term Technical Outlook
52-Week Range Analysis: Concord Drugs is currently trading near its 52-week low of ₹30.59, indicating potential value opportunity.
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: -37.88% | 3-year: +15.4% | 5-year: +147.33%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Concord Drugs Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹37.10 | ||
| 2024 | ₹37.32 | +0.59% | ₹37.88 |
| 2025 | ₹37.69 | +0.99% | ₹39.06 |
| 2026 | ₹36.78 | -2.41% | ₹38.87 |
| 2027 | ₹35.55 | -3.34% | ₹38.68 |
| 2028 | ₹36.45 | +2.53% | ₹38.49 |
| 2029 | ₹36.59 | +0.38% | ₹37.14 |
| 2030 | ₹36.95 | +0.98% | ₹38.30 |
| 2031 | ₹36.06 | -2.4% | ₹38.11 |
| 2032 | ₹34.85 | -3.35% | ₹37.92 |
| 2033 | ₹35.73 | +2.52% | ₹37.73 |
| 2034 | ₹35.86 | +0.36% | ₹36.40 |
| 2035 | ₹36.21 | +0.97% | ₹37.54 |
| 2036 | ₹35.33 | -2.43% | ₹37.35 |
| 2037 | ₹34.15 | -3.33% | ₹37.16 |
| 2038 | ₹35.01 | +2.51% | ₹36.97 |
| 2039 | ₹34.17 | -2.39% | ₹35.66 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Concord Drugs Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 31.34 Crore | Market valuation of Concord Drugs's shares. |
| Revenue (TTM) | 44.92 Crore | Total revenue generated by Concord Drugs over the past twelve months. |
| Net Income (TTM) | +47.24 Lakh | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +5.55% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +25.97% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-25.25% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
0.49 | Company's total debt divided by total shareholder equity. |
| Total Debt | 16.59 Crore | Sum of Concord Drugs's current & long-term financial obligations. |
Is Concord Drugs A Good Buy For Long Term?
Concord Drugs, a small-cap stock with a market capitalization of ₹31.34 crore, presents a mixed investment picture. While its five-year return of 59.15% is encouraging, the recent performance is concerning, showing a YTD loss of -39.77%. A significant debt of ₹16.59 crore (Q1 2024-25) against a net profit of ₹47.24 lakh (TTM) raises red flags. Although the profit margin is relatively healthy at 25.97%, the sharp revenue decline of -25.25% quarter-over-quarter warrants caution. Therefore, Concord Drugs is currently a not a good buy for long-term investors given the current risk profile. Further investigation into the reasons behind the revenue drop is crucial before considering any investment.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
